The Tolerx, Inc. Liquidating Trust
Records under this name other than patents The Tolerx, Inc. Liquidating Trust holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 7 of 7 · Back to The Tolerx, Inc. Liquidating Trust
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,541,443 | Anti-CD4 antibodies Lapsed on the fee record Ended Jun 2, 2017 · USPTO record | Lapsed on the fee record | Ended Jun 2, 2017 | USPTO record |
| US 6,056,956 | Non-depleting anti-CD4 monoclonal antibodies and tolerance induction Term ended Term ended May 2, 2017 · USPTO record | Term ended | Term ended May 2, 2017 | USPTO record |
| US 7,947,272 | Compositions and methods of tolerizing a primate to an antigen Lapsed on the fee record Ended May 24, 2015 · USPTO record | Lapsed on the fee record | Ended May 24, 2015 | USPTO record |
| US 6,767,996 | Altered antibodies and their preparation Formerly held Surrendered on reissue Surrendered on reissue Jan 1, 2013 · USPTO record | Surrendered on reissue | Surrendered on reissue Jan 1, 2013 | USPTO record |
| US 5,502,167 | CDR grafted humanised chimeric T-cell antibodies Term ended Term ended no later than Mar 26, 2016 · Low confidence | Term ended | Term ended no later than Mar 26, 2016 | Low confidence |
| US 5,670,150 | Non-depleting CD4-specific monoclonal antibodies for the treatment of insulin-dependent diabetes mellitus (IDDM) Term ended Term ended no later than Sep 23, 2017 · Low confidence | Term ended | Term ended no later than Sep 23, 2017 | Low confidence |
| US 5,690,933 | Monoclonal antibodies for inducing tolerance Term ended Term ended no later than Nov 25, 2017 · Low confidence | Term ended | Term ended no later than Nov 25, 2017 | Low confidence |